Trial Profile
Effect of Empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: Multi-Center placebo-controlled Double-Blind Randomized Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Mar 2022
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary)
- Indications Cardiovascular disorders
- Focus Therapeutic Use
- Acronyms EMBODY
- 17 Nov 2020 Results (n=96) of subanalysis assessing the time-course of renal function on baseline, weeks 4, 12 and 24 presented at the American Heart Association Scientific Sessions 2020
- 01 Sep 2020 Results of sub-group analysis presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology
- 10 Dec 2019 Status changed from active, no longer recruiting to completed.